Cancer medicine · 2026
Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liao Po-Wei, Ko Bor-Sheng, Su Yu-Chen, Chao Wei-Ting, Teng Chieh-Lin Jerry
Аннотация
BACKGROUND: Therapy for chronic lymphocytic leukemia (CLL) has shifted from chemoimmunotherapy to targeted agents such as Bruton's tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors. Approved first-line options include acalabrutinib, a second-generation BTK inhibitor, and the fixed-duration combination venetoclax-obinutuzumab, yet real-world head-to-head data are scarce.
METHODS: Using the TriNetX global federated health database, we retrospectively compared outcomes in treatment-naïve patients with TP53-unmutated CLL who received either regimen as initial therapy. After applying eligibility criteria and 1:1 propensity score matching, 669 matched pairs were analyzed. The primary endpoint was time to next treatment (TTNT); secondary endpoints included overall survival (OS) and adverse events.
RESULTS: The results showed that patients treated with venetoclax plus obinutuzumab had a significantly longer TTNT (median not reached vs. 47.7 months) and improved 4-year OS. Across all subgroups, the venetoclax-based regimen performed better. Cytopenias and infections were more common with venetoclax-obinutuzumab-neutropenia 54.3% versus 33.3%, thrombocytopenia 45.9% versus 31.9%, febrile neutropenia 7.1% versus 3.4%, and tumor lysis syndrome 6.3% versus 2.3%. Acalabrutinib caused fewer severe hematologic toxicities.
CONCLUSION: In real-world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first-line therapy in patients with TP53 wild-type CLL.
METHODS: Using the TriNetX global federated health database, we retrospectively compared outcomes in treatment-naïve patients with TP53-unmutated CLL who received either regimen as initial therapy. After applying eligibility criteria and 1:1 propensity score matching, 669 matched pairs were analyzed. The primary endpoint was time to next treatment (TTNT); secondary endpoints included overall survival (OS) and adverse events.
RESULTS: The results showed that patients treated with venetoclax plus obinutuzumab had a significantly longer TTNT (median not reached vs. 47.7 months) and improved 4-year OS. Across all subgroups, the venetoclax-based regimen performed better. Cytopenias and infections were more common with venetoclax-obinutuzumab-neutropenia 54.3% versus 33.3%, thrombocytopenia 45.9% versus 31.9%, febrile neutropenia 7.1% versus 3.4%, and tumor lysis syndrome 6.3% versus 2.3%. Acalabrutinib caused fewer severe hematologic toxicities.
CONCLUSION: In real-world practice, venetoclax plus obinutuzumab was associated with longer TTNT and improved OS compared to acalabrutinib as first-line therapy in patients with TP53 wild-type CLL.